These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3710299)

  • 1. Biochemical and pharmacological studies on the interaction of PK 10169 and its subfractions with human platelets.
    Brace LD; Fareed J; Tomeo J; Issleib S
    Haemostasis; 1986; 16(2):93-105. PubMed ID: 3710299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-induced platelet aggregation: dose/response relationships for a low molecular weight heparin derivative (PK 10169) and its subfractions.
    Brace LD; Fareed J
    Thromb Res; 1986 Jun; 42(6):769-82. PubMed ID: 3726798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169).
    Walenga JM; Fareed J; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):17-25. PubMed ID: 3883497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationale behind the development of low molecular weight heparin derivatives.
    Hirsh J; Ofosu F; Buchanan M
    Semin Thromb Hemost; 1985 Jan; 11(1):13-6. PubMed ID: 2579436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-induced thrombocytopenia platelet aggregation studies in the presence of heparin fractions or semi-synthetic analogues of various molecular weights and anticoagulant activities.
    Blockmans D; Bounameaux H; Vermylen J; Verstraete M
    Thromb Haemost; 1986 Feb; 55(1):90-3. PubMed ID: 3518134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.
    Bratt G; Törnebohm E; Lockner D; Bergström K
    Thromb Haemost; 1985 Apr; 53(2):208-11. PubMed ID: 4024029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of heparin fractions: some overlooked considerations.
    Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):227-36. PubMed ID: 3898374
    [No Abstract]   [Full Text] [Related]  

  • 9. Heparin, its fractions, fragments and derivatives. Some newer perspectives.
    Fareed J
    Semin Thromb Hemost; 1985 Jan; 11(1):1-9. PubMed ID: 3919446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of heparin and heparin fractions on platelet aggregation.
    Salzman EW; Rosenberg RD; Smith MH; Lindon JN; Favreau L
    J Clin Invest; 1980 Jan; 65(1):64-73. PubMed ID: 6243142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously.
    Bergqvist D; Hedner U; Sjörin E; Holmer E
    Thromb Res; 1983 Nov; 32(4):381-91. PubMed ID: 6658720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demonstration of a direct anti-factor Xa activity in certain heparin-related glycosaminoglycans.
    Larsson A; Fransson LA; Lewis WE
    Thromb Res; 1982 Jun; 26(6):401-9. PubMed ID: 7112518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new low molecular weight heparin fragment (PK 10169): in vitro and in vivo studies.
    Vinazzer H; Woler M
    Haemostasis; 1986; 16(2):106-15. PubMed ID: 2423420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new low molecular weight heparin fragment (PK 10169): in vitro and in vivo studies.
    Vinazzer H; Woler M
    Thromb Res; 1985 Oct; 40(2):135-46. PubMed ID: 3878009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet aggregation studies for the diagnosis of heparin-induced thrombocytopenia.
    Isenhart CE; Brandt JT
    Am J Clin Pathol; 1993 Mar; 99(3):324-30. PubMed ID: 8447295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma.
    Ofosu FA; Modi G; Cerskus AL; Hirsh J; Blajchman MA
    Thromb Res; 1982 Nov; 28(4):487-97. PubMed ID: 7164033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III.
    Baruch D; Lindhout T; Wagenvoord R; Hemker HC
    Haemostasis; 1986; 16(2):71-81. PubMed ID: 3086193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From heparin to heparin fractions and derivatives.
    Coyne E
    Semin Thromb Hemost; 1985 Jan; 11(1):10-2. PubMed ID: 3883496
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro evaluation of heparin fractions: old vs. new methods.
    Walenga JM; Fareed J; Hoppensteadt D; Emanuele RM
    Crit Rev Clin Lab Sci; 1986; 22(4):361-89. PubMed ID: 2936571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The acceleration of the inhibition of platelet prothrombinase complex by heparin.
    Ellis V; Scully MF; Kakkar VV
    Biochem J; 1986 Jan; 233(1):161-5. PubMed ID: 3954724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.